Antibody libraries have become vital discovery and screening tools in research and drug discovery. Though deceptively simple, these collections of antigen-binding antibody fragments (or the DNA sequences that encode them) dramatically speed up the process of identifying and developing novel antibodies for a range of applications. For example, “panning” antibody libraries led to the quick isolation of the Ab1 antibody that tightly binds the SARS-CoV-2 spike protein, followed by the unusually rapid development of effective COVID-19 vaccines. Antibody libraries are also used to generate biomarkers for early cancer detection, generate antibody tools that bind and stop intracellular processes, and facilitate development of other high affinity antibodies with minimal off-target effects. This article discusses antibody libraries today and how their role in discovering novel antibodies has made them indispensable in research and drug discovery.
Producing diversity faster
Another benefit of antibody libraries is the ability to change and refine selection parameters. “The strength of antibody libraries lies in their ability to produce diverse candidate molecules quickly and flexibly,” says Ruizhi Wang, Founder and CEO at Abselion. Libraries allow quick identification of antibodies that will bind to targets—a powerful alternative to the traditional but slower whole-animal method of monoclonal antibody development. This is particularly valuable in developing therapeutics that advance at a quick pace. “They help accelerate the identification of lead candidates with high affinity and functional specificity, while offering greater control over isotype selection, epitope targeting, and sequence optimization.”
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Evaluating the binding candidates can be an iterative process that winnows them down, refining according to relevant properties. “Many researchers use antibody libraries as a critical starting point for discovering and refining therapeutic antibodies, particularly in fields like immuno-oncology, where time-to-decision and functional relevance are essential,” says Wang. “Libraries allow for broad screening of potential binders, followed by iterative optimization based on expression levels, yield, and performance in cell-based systems.” Abelion’s Amperia™ platform helps researchers evaluate candidates, using a redox electrochemical detection sensor for rapid, concentration-based quantification.
Agenus, a biotech company researching antibody-based immunotherapies for cancers such as colorectal, pancreatic, and cervical, uses Amperia™ to measure monoclonal antibody titers during optimization. “The ability to obtain rapid, concentration-based data helped accelerate decision-making and streamline the path toward selecting top candidates for further development,” says Wang.
As with instrumentation, screening strategies also continue to evolve. “There’s a growing emphasis on integrating early analytics—such as expression profiling or quantification—to support faster, better-informed decisions,” says Wang. “These checkpoints, once considered downstream, are now becoming part of the front end of discovery.”
Evaluating antibody candidates
Antibody libraries allow fast screening of many antibodies simultaneously, speeding identification of the best binding candidates for further evaluation. “The success of the antibody discovery process depends on the quality and diversity of the library, and additional testing is required to prove that the identified candidates have the desired binding, stability, and biological effects,” says Diana Bonilla Escobar, Director of Scientific Commercialization at Cytek Biosciences.
Cytek uses full-spectrum flow cytometry to evaluate the functionality of antibody candidates, including antibody recognition, internalization, and a multitude of cellular responses to antibody binding. “The capacity to simultaneously measure multiple markers and cellular functionality streamlines the optimization of antibody candidates, providing a better understanding of antibody performance in a biologically relevant cellular context,” says Bonilla Escobar, who notes that researchers using flow cytometry can consult curated antibody libraries to guide their reagent selection. For example, Antibodypedia and the Resource Identification Portal catalog commercially available antibodies based on scientific validation data.
Cytek’s full-spectrum flow cytometers are a valuable tool in cancer immunotherapy research. “Antibody libraries can be used to identify candidates that bind immune checkpoints or tumor-associated antigens, which are key targets for reactivating antitumor immune responses,” says Bonilla Escobar. Screening with Cytek’s tools allows you to identify antibody candidates that bind targets with higher affinity and specificity, as well as to assay their functional activity. “This approach accelerates the transition from discovery to candidate validation,” she says.
Developing new therapeutics
Phage display is a method used to identify antibodies within the library that bind to specific targets of interest. Bacteriophage viruses are engineered to express on their surfaces a library of antibody fragments (Fabs). Fabs that bind to the targets are then selected for further study. One of the biggest advantages of antibody libraries, notes John Cardone, Marketing Manager in Custom Antibodies at Bio-Rad Laboratories, is the opportunity to change experimental controls as needed. For example, Bio-Rad’s Pioneer™ Antibody Library—one of the largest fully human, synthetic Fab phage display libraries—is designed to identify therapeutic antibody candidates under specific conditions, such as a particular pH range. “This flexibility allows researchers to guide the selection process and experimental conditions to isolate, for instance, pH-sensitive antibodies—something that is impossible to achieve through standard immunization approaches,” says Cardone.
A recent collaboration between Salipro Biotech and Bio-Rad combined the former’s Salipro® proprietary nano-membrane platform with the latter’s Pioneer™ Antibody Discovery Platform, with an aim to identify candidate antibodies to a transmembrane G-protein coupled receptor (GPCR), CXC chemokine receptor 4 (CXCR4). Salipro® stabilized membrane proteins embedded in a lipid membrane, while the Pioneer™ Antibody Discovery Platform identified antibodies that bind to them with high affinity.
The collaboration resulted in the discovery of novel human antibodies to CXCR4 with affinities higher than a current anti-cancer therapeutic, an anti-CXCR4 monoclonal antibody called ulocuplumab. “These new CXCR4-targeting antibodies offer the potential for enhanced efficacy and novel immuno-oncology therapeutic avenues,” says Cardone. “By making previously undruggable membrane proteins accessible, this collaboration enhances the efficiency and success rate of developing next-generation therapeutics, pushing the boundaries of what is possible in drug discovery.”